Cargando…
Could Antinuclear Antibody Positivity Be a Factor Affecting Treatment Response in Immune Thrombocytopenia Patients on Eltrombopag?
OBJECTIVE: Eltrombopag remains a prominent option in the treatment of steroid-dependent or steroid-refractory immune thrombocytopenia (ITP) patients. Unfortunately, not all patients respond to eltrombopag. Antinuclear antibody (ANA) positivity can be seen at rates of up to 30% in ITP patients. Despi...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Galenos Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886267/ https://www.ncbi.nlm.nih.gov/pubmed/34162172 http://dx.doi.org/10.4274/tjh.galenos.2021.2021.0183 |
_version_ | 1784660628275724288 |
---|---|
author | Baysal, Mehmet Baş, Volkan Ümit, Elif Kırkızlar, Hakkı Onur Demir, Ahmet Muzaffer |
author_facet | Baysal, Mehmet Baş, Volkan Ümit, Elif Kırkızlar, Hakkı Onur Demir, Ahmet Muzaffer |
author_sort | Baysal, Mehmet |
collection | PubMed |
description | OBJECTIVE: Eltrombopag remains a prominent option in the treatment of steroid-dependent or steroid-refractory immune thrombocytopenia (ITP) patients. Unfortunately, not all patients respond to eltrombopag. Antinuclear antibody (ANA) positivity can be seen at rates of up to 30% in ITP patients. Despite being widely used, more markers to predict the response to eltrombopag are still needed. In the present study, we aimed to show the association between ANA positivity and eltrombopag response in ITP patients. MATERIALS AND METHODS: Patients who were diagnosed with ITP in the Trakya University Faculty of Medicine’s Department of Hematology and who underwent eltrombopag treatment due to their resistance to steroids and other treatments were included in our study. ANA measurement was performed by indirect fluorescent antibody method and titers of 1:160 and above were considered positive. ANA measurements were made before starting eltrombopag. RESULTS: Forty-five patients were included in our study, 33 being women and 12 men. The mean age of the patients was 45.73 years. There were 14 patients with ANA positivity and 31 patients were found to be ANA-negative. Response rates were higher in ANA-negative patients compared to ANA-positive patients in the 1(st) and 6(th) months of eltrombopag treatment (p<0.05). CONCLUSION: ANA positivity in ITP may indicate unresponsiveness to eltrombopag treatment, a finding that should be further supported by prospective studies involving more patients. |
format | Online Article Text |
id | pubmed-8886267 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Galenos Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-88862672022-03-11 Could Antinuclear Antibody Positivity Be a Factor Affecting Treatment Response in Immune Thrombocytopenia Patients on Eltrombopag? Baysal, Mehmet Baş, Volkan Ümit, Elif Kırkızlar, Hakkı Onur Demir, Ahmet Muzaffer Turk J Haematol Research Article OBJECTIVE: Eltrombopag remains a prominent option in the treatment of steroid-dependent or steroid-refractory immune thrombocytopenia (ITP) patients. Unfortunately, not all patients respond to eltrombopag. Antinuclear antibody (ANA) positivity can be seen at rates of up to 30% in ITP patients. Despite being widely used, more markers to predict the response to eltrombopag are still needed. In the present study, we aimed to show the association between ANA positivity and eltrombopag response in ITP patients. MATERIALS AND METHODS: Patients who were diagnosed with ITP in the Trakya University Faculty of Medicine’s Department of Hematology and who underwent eltrombopag treatment due to their resistance to steroids and other treatments were included in our study. ANA measurement was performed by indirect fluorescent antibody method and titers of 1:160 and above were considered positive. ANA measurements were made before starting eltrombopag. RESULTS: Forty-five patients were included in our study, 33 being women and 12 men. The mean age of the patients was 45.73 years. There were 14 patients with ANA positivity and 31 patients were found to be ANA-negative. Response rates were higher in ANA-negative patients compared to ANA-positive patients in the 1(st) and 6(th) months of eltrombopag treatment (p<0.05). CONCLUSION: ANA positivity in ITP may indicate unresponsiveness to eltrombopag treatment, a finding that should be further supported by prospective studies involving more patients. Galenos Publishing 2022-03 2022-02-23 /pmc/articles/PMC8886267/ /pubmed/34162172 http://dx.doi.org/10.4274/tjh.galenos.2021.2021.0183 Text en © Copyright 2022 by Turkish Society of Hematology / Turkish Journal of Hematology, Published by Galenos Publishing House. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Baysal, Mehmet Baş, Volkan Ümit, Elif Kırkızlar, Hakkı Onur Demir, Ahmet Muzaffer Could Antinuclear Antibody Positivity Be a Factor Affecting Treatment Response in Immune Thrombocytopenia Patients on Eltrombopag? |
title | Could Antinuclear Antibody Positivity Be a Factor Affecting Treatment Response in Immune Thrombocytopenia Patients on Eltrombopag? |
title_full | Could Antinuclear Antibody Positivity Be a Factor Affecting Treatment Response in Immune Thrombocytopenia Patients on Eltrombopag? |
title_fullStr | Could Antinuclear Antibody Positivity Be a Factor Affecting Treatment Response in Immune Thrombocytopenia Patients on Eltrombopag? |
title_full_unstemmed | Could Antinuclear Antibody Positivity Be a Factor Affecting Treatment Response in Immune Thrombocytopenia Patients on Eltrombopag? |
title_short | Could Antinuclear Antibody Positivity Be a Factor Affecting Treatment Response in Immune Thrombocytopenia Patients on Eltrombopag? |
title_sort | could antinuclear antibody positivity be a factor affecting treatment response in immune thrombocytopenia patients on eltrombopag? |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886267/ https://www.ncbi.nlm.nih.gov/pubmed/34162172 http://dx.doi.org/10.4274/tjh.galenos.2021.2021.0183 |
work_keys_str_mv | AT baysalmehmet couldantinuclearantibodypositivitybeafactoraffectingtreatmentresponseinimmunethrombocytopeniapatientsoneltrombopag AT basvolkan couldantinuclearantibodypositivitybeafactoraffectingtreatmentresponseinimmunethrombocytopeniapatientsoneltrombopag AT umitelif couldantinuclearantibodypositivitybeafactoraffectingtreatmentresponseinimmunethrombocytopeniapatientsoneltrombopag AT kırkızlarhakkıonur couldantinuclearantibodypositivitybeafactoraffectingtreatmentresponseinimmunethrombocytopeniapatientsoneltrombopag AT demirahmetmuzaffer couldantinuclearantibodypositivitybeafactoraffectingtreatmentresponseinimmunethrombocytopeniapatientsoneltrombopag |